Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity-based compensation to a new employee. The package includes options to purchase 4,200 shares at an exercise price of $9.75 per share and restricted stock units (RSUs) for 2,100 shares. The grants were made under the company's 2020 Inducement Plan, approved under NYSE Rule 303A.08's inducement exception.

Arcus Biosciences (NYSE:RCUS) announced that its investigational CD73 inhibitor, quemliclustat, received orphan drug designation from the FDA for pancreatic cancer treatment. The designation provides benefits including tax credits, user fee exemptions, and potential 7-year market exclusivity upon approval.

Phase 1 ARC-8 study results showed promising median overall survival of 15.7 months with quemliclustat-based regimens, surpassing historical chemotherapy benchmarks. The company's Phase 3 PRISM-1 trial, evaluating quemliclustat plus chemotherapy in 610 first-line metastatic pancreatic cancer patients, is expected to complete enrollment by end of 2025.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity-based compensation to six new employees. The awards include 54,800 stock options at an exercise price of $8.50 per share and 27,550 restricted stock units (RSUs). These equity grants were made under the company's 2020 Inducement Plan, approved under NYSE Rule 303A.08's inducement exception.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced new employment inducement grants. The company's Compensation Committee approved equity awards for one new employee, including options to purchase 2,850 shares at $8.63 per share and restricted stock units for 1,450 shares. The grants were made under the company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's inducement exception.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has granted equity awards to two new employees. The compensation package includes options to purchase 8,400 shares of common stock at $9.85 per share (the closing price on June 9, 2025) and restricted stock units for 4,200 shares. These grants were made under the company's 2020 Inducement Plan, which was established in January 2020 under NYSE Listed Company Manual Rule 303A.08's inducement exception.

Arcus Biosciences (NYSE:RCUS) reported promising initial data from the ARC-20 study evaluating casdatifan (HIF-2a inhibitor) plus cabozantinib (tyrosine kinase inhibitor) in metastatic kidney cancer patients. The combination demonstrated a 46% confirmed overall response rate in patients with minimum 12-week follow-up. Among 24 efficacy-evaluable patients, 4% achieved complete response, 42% partial response, and 50% stable disease, with only 4% showing disease progression. The safety profile was manageable with no unexpected risks among 42 safety-evaluable patients. Based on these positive results, Arcus plans to initiate two key trials: PEAK-1, a Phase 3 study in immunotherapy-experienced patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line patients.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has announced new employment inducement grants. The company's Compensation Committee granted equity awards to two new employees, including: - Options to purchase 13,400 shares at an exercise price of $9.02 per share (closing price as of May 23, 2025) - Restricted stock units (RSUs) to acquire 13,400 shares These equity awards were granted under the company's 2020 Inducement Plan, which was approved by the Board of Directors in January 2020 under the NYSE Listed Company Manual Rule 303A.08 inducement exception.

Arcus Biosciences (NYSE:RCUS) has granted equity-based compensation to three new employees as part of their inducement package. The awards include:

- Stock options to purchase 21,250 shares at an exercise price of $8.53 per share (closing price as of May 8, 2025)

- Restricted stock units (RSUs) totaling 10,650 shares

These equity awards were granted under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08's "inducement exception."

Arcus Biosciences (NYSE:RCUS) reported Q1 2025 financial results and pipeline updates. The company ended Q1 with $1.0 billion in cash. Key highlights include upcoming data presentation for casdatifan plus cabozantinib in renal cell carcinoma at ASCO 2025. Previous data showed promising results with >30% confirmed response rates in two cohorts and 9.7-month median PFS in the 50mg cohort. The company plans to initiate PEAK-1 Phase 3 study in Q2 2025. Financial results showed revenues of $28 million (vs $145M in Q1 2024), R&D expenses of $122 million (vs $109M), and a net loss of $112 million (vs $4M). Arcus expects 2025 revenue between $75-90 million and has sufficient funding through initial pivotal readouts for key programs.